{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T03:53:35Z","timestamp":1785556415014,"version":"3.56.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"49","license":[{"start":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T00:00:00Z","timestamp":1763337600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T00:00:00Z","timestamp":1763337600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["DA 1143\/6-1"],"award-info":[{"award-number":["DA 1143\/6-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncogene"],"published-print":{"date-parts":[[2025,12,18]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Breast cancer (BC)-derived bone metastases colonize bone and drive severe bone degradation through complex interactions with bone-resorbing osteoclasts (OCs). Subsequent bone resorption liberates matrix-stored factors, such as TGF-\u03b2 and calcium, which further stimulate tumor proliferation and exacerbate bone destruction. Myostatin (Mstn), a member of the TGF-\u03b2 superfamily, is known to enhance OC differentiation and bone resorption in models of musculoskeletal disease; however, its role in BC-associated bone lesions and metastases remains unknown. Here, we demonstrate that bone metastases from BC patients express Mstn, predominantly localized at the osteoclast-rich bone\u2013tumor interface. In vitro, both direct and indirect interactions between BC cells and OC precursors significantly increased OC formation and resorptive activity. Antibody-mediated blockade of Mstn attenuated these effects by inhibiting SMAD2 phosphorylation. In vivo, targeting Mstn in 4T1 and MDA-MB-231 murine models of BC-induced bone destruction resulted in elevated bone density, increased muscle mass, and reduced OC numbers compared to controls. Furthermore, anti-Mstn treatment decreased the burden of bone metastases in MDA-MB-231-bearing mice. Collectively, these findings identify Mstn as a previously unrecognized driver of BC-induced osteolysis and metastases, highlighting its potential as a therapeutic target in metastatic BC.<\/jats:p>","DOI":"10.1038\/s41388-025-03622-7","type":"journal-article","created":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T21:05:33Z","timestamp":1763413533000},"page":"4781-4795","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Pharmacological inhibition of myostatin effectively ameliorates osteolytic lesions in syngeneic and xenograft breast cancer mouse models"],"prefix":"10.1038","volume":"44","author":[{"given":"Julia","family":"Reinhardt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Berno","family":"Dankbar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabienne","family":"Geers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenie","family":"Werbenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christiane","family":"Geyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annalen","family":"Bleckmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8188-0163","authenticated-orcid":false,"given":"Kerstin","family":"Menck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Gr\u00f6zinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7609-5021","authenticated-orcid":false,"given":"Wolfgang","family":"Hartmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joke","family":"Tio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carsten","family":"H\u00f6ltke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Helfen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9261-8753","authenticated-orcid":false,"given":"Andreas","family":"Lodberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa","family":"Al-Qasemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise","family":"Beckmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"B\u00f6decker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Kleimann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Wessendorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deniz","family":"Wawersig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6514-0416","authenticated-orcid":false,"given":"Thomas","family":"Pap","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7136-2779","authenticated-orcid":false,"given":"Corinna","family":"Wehmeyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,17]]},"reference":[{"key":"3622_CR1","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/978-3-030-20301-6_7","volume":"1152","author":"RK Tahara","year":"2019","unstructured":"Tahara RK, Brewer TM, Theriault RL, Ueno NT. Bone metastasis of breast cancer. Adv Exp Med Biol. 2019;1152:105\u201329.","journal-title":"Adv Exp Med Biol"},{"key":"3622_CR2","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1038\/nrc3055","volume":"11","author":"KN Weilbaecher","year":"2011","unstructured":"Weilbaecher KN, Guise TA, McCauley LK. Cancer to bone: a fatal attraction. Nat Rev Cancer. 2011;11:411\u201325.","journal-title":"Nat Rev Cancer"},{"key":"3622_CR3","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1615\/CritRevEukarGeneExpr.v10.i2.50","volume":"10","author":"JM Chirgwin","year":"2000","unstructured":"Chirgwin JM, Guise TA. Molecular mechanisms of tumor-bone interactions in osteolytic metastases. Crit Rev Eukaryot Gene Expr. 2000;10:159\u201378.","journal-title":"Crit Rev Eukaryot Gene Expr"},{"key":"3622_CR4","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.maturitas.2016.01.001","volume":"86","author":"L Kiesel","year":"2016","unstructured":"Kiesel L, Kohl A. Role of the RANK\/RANKL pathway in breast cancer. Maturitas. 2016;86:10\u201316.","journal-title":"Maturitas"},{"key":"3622_CR5","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1038\/nrc867","volume":"2","author":"GR Mundy","year":"2002","unstructured":"Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer. 2002;2:584\u201393.","journal-title":"Nat Rev Cancer"},{"key":"3622_CR6","doi-asserted-by":"publisher","first-page":"335","DOI":"10.5306\/wjco.v5.i3.335","volume":"5","author":"N Rucci","year":"2014","unstructured":"Rucci N, Sanit\u00e0 P, Monache SD, Alesse E, Angelucci A. Molecular pathogenesis of bone metastases in breast cancer: Proven and emerging therapeutic targets. World J Clin Oncol. 2014;5:335\u201347.","journal-title":"World J Clin Oncol"},{"key":"3622_CR7","doi-asserted-by":"publisher","first-page":"2609","DOI":"10.1158\/1535-7163.MCT-07-0234","volume":"6","author":"LA Kingsley","year":"2007","unstructured":"Kingsley LA, Fournier PGJ, Chirgwin JM, Guise TA. Molecular biology of bone metastasis. Mol Cancer Ther. 2007;6:2609\u201317.","journal-title":"Mol Cancer Ther"},{"key":"3622_CR8","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1002\/ijc.23113","volume":"121","author":"S-K Leivonen","year":"2007","unstructured":"Leivonen S-K, K\u00e4h\u00e4ri V-MMINI. REVIEW Transforming growth factor-beta signaling in cancer invasion and metastasis. Int J Cancer. 2007;121:2119\u201324.","journal-title":"Int J Cancer"},{"key":"3622_CR9","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1002\/ijc.23113","volume":"121","author":"SK Leivonen","year":"2007","unstructured":"Leivonen SK, K\u00e4h\u00e4ri VM. Transforming growth factor-beta signaling in cancer invasion and metastasis. Int J Cancer. 2007;121:2119\u201324.","journal-title":"Int J Cancer"},{"key":"3622_CR10","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1002\/jcp.22272","volume":"225","author":"G Leto","year":"2010","unstructured":"Leto G. Activin A and bone metastasis. J Cell Physiol. 2010;225:302\u20139.","journal-title":"J Cell Physiol"},{"key":"3622_CR11","doi-asserted-by":"publisher","first-page":"2633","DOI":"10.1002\/jbmr.142","volume":"25","author":"AD Chantry","year":"2010","unstructured":"Chantry AD, Heath D, Mulivor AW, Pearsall S, Baud\u2019Huin M, Coulton L, et al. Inhibiting activin-A signaling stimulates bone formation and prevents cancer-induced bone destruction in vivo. J Bone Min Res. 2010;25:2633\u201346.","journal-title":"J Bone Min Res"},{"key":"3622_CR12","doi-asserted-by":"publisher","first-page":"3531","DOI":"10.1242\/jcs.02482","volume":"118","author":"S McCroskery","year":"2005","unstructured":"McCroskery S, Thomas M, Platt L, Hennebry A, Nishimura T, McLeay L, et al. Improved muscle healing through enhanced regeneration and reduced fibrosis in myostatin-null mice. J Cell Sci. 2005;118:3531\u201341.","journal-title":"J Cell Sci"},{"key":"3622_CR13","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/387083a0","volume":"387","author":"AC McPherron","year":"1997","unstructured":"McPherron AC, Lawler AM, Lee SJ. Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member. Nature. 1997;387:83\u201390.","journal-title":"Nature"},{"key":"3622_CR14","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.cellsig.2004.08.003","volume":"17","author":"B Philip","year":"2005","unstructured":"Philip B, Lu Z, Gao Y. Regulation of GDF-8 signaling by the p38 MAPK. Cell Signal. 2005;17:365\u201375.","journal-title":"Cell Signal"},{"key":"3622_CR15","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.bone.2008.08.126","volume":"44","author":"E Kellum","year":"2009","unstructured":"Kellum E, Starr H, Arounleut P, Immel D, Fulzele S, Wenger K, et al. Myostatin (GDF-8) deficiency increases fracture callus size, Sox-5 expression, and callus bone volume. Bone. 2009;44:17\u201323.","journal-title":"Bone"},{"key":"3622_CR16","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1002\/ar.a.10044","volume":"272","author":"MW Hamrick","year":"2003","unstructured":"Hamrick MW. Increased bone mineral density in the femora of GDF8 knockout mice. Anat Rec A Discov Mol Cell Evol Biol. 2003;272:388\u201391.","journal-title":"Anat Rec A Discov Mol Cell Evol Biol"},{"key":"3622_CR17","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1016\/j.bone.2007.02.012","volume":"40","author":"MW Hamrick","year":"2007","unstructured":"Hamrick MW, Shi X, Zhang W, Pennington C, Thakore H, Haque M, et al. Loss of myostatin (GDF8) function increases osteogenic differentiation of bone marrow-derived mesenchymal stem cells but the osteogenic effect is ablated with unloading. Bone. 2007;40:1544\u201353.","journal-title":"Bone"},{"key":"3622_CR18","doi-asserted-by":"publisher","first-page":"1828","DOI":"10.1249\/MSS.0b013e3182178bb4","volume":"43","author":"DL Allen","year":"2011","unstructured":"Allen DL, Hittel DS, McPherron AC. Expression and function of myostatin in obesity, diabetes, and exercise adaptation. Med Sci Sports Exerc. 2011;43:1828\u201335.","journal-title":"Med Sci Sports Exerc"},{"key":"3622_CR19","doi-asserted-by":"publisher","unstructured":"Yang M, Liu C, Jiang N, Liu Y, Luo S, Li C, et al. Myostatin: a potential therapeutic target for metabolic syndrome. Front Endocrinol. 2023;14. https:\/\/doi.org\/10.3389\/FENDO.2023.1181913.","DOI":"10.3389\/FENDO.2023.1181913"},{"key":"3622_CR20","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1096\/fj.10-176917","volume":"25","author":"L Zhang","year":"2011","unstructured":"Zhang L, Rajan V, Lin E, Hu Z, Han HQ, Zhou X, et al. Pharmacological inhibition of myostatin suppresses systemic inflammation and muscle atrophy in mice with chronic kidney disease. FASEB J. 2011;25:1653\u201363.","journal-title":"FASEB J"},{"key":"3622_CR21","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1038\/nm.3917","volume":"21","author":"B Dankbar","year":"2015","unstructured":"Dankbar B, Fennen M, Brunert D, Hayer S, Frank S, Wehmeyer C, et al. Myostatin is a direct regulator of osteoclast differentiation and its inhibition reduces inflammatory joint destruction in mice. Nat Med. 2015;21:1085\u201390.","journal-title":"Nat Med"},{"key":"3622_CR22","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.cell.2010.07.011","volume":"142","author":"X Zhou","year":"2010","unstructured":"Zhou X, Wang JL, Lu J, Song Y, Kwak KS, Jiao Q, et al. Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival. Cell. 2010;142:531\u201343.","journal-title":"Cell"},{"key":"3622_CR23","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s13539-011-0049-z","volume":"3","author":"S Busquets","year":"2012","unstructured":"Busquets S, Toledo M, Orp\u00ed M, Massa D, Porta M, Capdevila E, et al. Myostatin blockage using actRIIB antagonism in mice bearing the Lewis lung carcinoma results in the improvement of muscle wasting and physical performance. J Cachexia Sarcopenia Muscle. 2012;3:37\u201343.","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"3622_CR24","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.breast.2017.11.010","volume":"37","author":"C Wallner","year":"2018","unstructured":"Wallner C, Drysch M, Becerikli M, Jaurich H, Wagner JM, Dittfeld S, et al. Interaction with the GDF8\/11 pathway reveals treatment options for adenocarcinoma of the breast. Breast. 2018;37:134\u201341.","journal-title":"Breast"},{"key":"3622_CR25","doi-asserted-by":"publisher","unstructured":"Liu S, Liu B, Zhao Q, Shi J, Gu Y, Guo Y, et al. Down-regulated FST expression is involved in the poor prognosis of triple-negative breast cancer. Cancer Cell Int 2021;21. https:\/\/doi.org\/10.1186\/S12935-021-01977-X.","DOI":"10.1186\/S12935-021-01977-X"},{"key":"3622_CR26","doi-asserted-by":"publisher","unstructured":"Seachrist DD, Sizemore ST, Johnson E, Abdul-Karim FW, Weber Bonk KL, Keri RA Follistatin is a metastasis suppressor in a mouse model of HER2-positive breast cancer. Breast Cancer Res. 2017;19. https:\/\/doi.org\/10.1186\/S13058-017-0857-Y.","DOI":"10.1186\/S13058-017-0857-Y"},{"key":"3622_CR27","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.21037\/atm-21-4052","volume":"9","author":"Y Pan","year":"2021","unstructured":"Pan Y, Lin Y, Mi C. Clinicopathological characteristics and prognostic risk factors of breast cancer patients with bone metastasis. Ann Transl Med. 2021;9:1340\u20131340.","journal-title":"Ann Transl Med"},{"key":"3622_CR28","doi-asserted-by":"publisher","unstructured":"Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. https:\/\/doi.org\/10.1158\/1078-0432.CCR-06-3045.","DOI":"10.1158\/1078-0432.CCR-06-3045"},{"key":"3622_CR29","doi-asserted-by":"publisher","unstructured":"Trivedi T, Pagnotti GM, Guise TA, Mohammad KS. The role of tgf-\u03b2 in bone metastases. Biomolecules. 2021;11. https:\/\/doi.org\/10.3390\/BIOM11111643.","DOI":"10.3390\/BIOM11111643"},{"key":"3622_CR30","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.bbadis.2008.01.006","volume":"1782","author":"KJ Gordon","year":"2008","unstructured":"Gordon KJ, Blobe GC. Role of transforming growth factor-beta superfamily signaling pathways in human disease. Biochim Biophys Acta. 2008;1782:197\u2013228.","journal-title":"Biochim Biophys Acta"},{"key":"3622_CR31","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/s10585-006-9010-5","volume":"23","author":"G Leto","year":"2006","unstructured":"Leto G, Incorvaia L, Badalamenti G, Tumminello FM, Gebbia N, Flandina C, et al. Activin A circulating levels in patients with bone metastasis from breast or prostate cancer. Clin Exp Metastasis. 2006;23:117\u201322.","journal-title":"Clin Exp Metastasis"},{"key":"3622_CR32","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/nrc2853","volume":"10","author":"H Ikushima","year":"2010","unstructured":"Ikushima H, Miyazono K. TGFbeta signalling: a complex web in cancer progression. Nat Rev Cancer. 2010;10:415\u201324.","journal-title":"Nat Rev Cancer"},{"key":"3622_CR33","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.mce.2004.02.016","volume":"225","author":"FM Reis","year":"2004","unstructured":"Reis FM, Luisi S, Carneiro MM, Cobellis L, Federico M, Camargos AF, et al. Activin, inhibin and the human breast. Mol Cell Endocrinol. 2004;225:77\u201382.","journal-title":"Mol Cell Endocrinol"},{"key":"3622_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.acthis.2005.11.002","volume":"108","author":"I Mylonas","year":"2006","unstructured":"Mylonas I, Makovitzky J, Hoeing A, Richter DU, Vogl J, Schulze S, et al. Inhibin\/activin subunits beta-A (-\u03b2A) and beta-B (-\u03b2B) are differentially localised in normal, hyperplastic and malignant human endometrial tissue. Acta Histochem. 2006;108:1\u201311.","journal-title":"Acta Histochem"},{"key":"3622_CR35","first-page":"3783","volume":"63","author":"JS Jeruss","year":"2003","unstructured":"Jeruss JS, Sturgis CD, Rademaker AW, Woodruff TK. Down-regulation of activin, activin receptors, and Smads in high-grade breast cancer. Cancer Res. 2003;63:3783\u201390.","journal-title":"Cancer Res"},{"key":"3622_CR36","doi-asserted-by":"publisher","unstructured":"Yu Z, Cheng L, Liu X, Zhang L, Cao H Increased Expression of INHBA is correlated with poor prognosis and high immune infiltrating level in breast cancer. Front. Bioinform. 2022;2. https:\/\/doi.org\/10.3389\/FBINF.2022.729902.","DOI":"10.3389\/FBINF.2022.729902"},{"key":"3622_CR37","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/8756-3282(94)90703-X","volume":"15","author":"T Taube","year":"1994","unstructured":"Taube T, Elomaa I, Blomqvist C, Beneton MNC, Kanis JA. Histomorphometric evidence for osteoclast-mediated bone resorption in metastatic breast cancer. Bone. 1994;15:161\u20136.","journal-title":"Bone"},{"key":"3622_CR38","doi-asserted-by":"publisher","unstructured":"Bashir M, Damineni S, Mukherjee G, Kondaiah P Activin-A signaling promotes epithelial-mesenchymal transition, invasion, and metastatic growth of breast cancer. NPJ Breast Cancer 2015;1. https:\/\/doi.org\/10.1038\/NPJBCANCER.2015.7.","DOI":"10.1038\/NPJBCANCER.2015.7"},{"key":"3622_CR39","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/370341a0","volume":"370","author":"JL Wrana","year":"1994","unstructured":"Wrana JL, Attisano L, Wieser R, Ventura F, Massagu\u00e9 J. Mechanism of activation of the TGF-beta receptor. Nature. 1994;370:341\u20137.","journal-title":"Nature"},{"key":"3622_CR40","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.cyto.2004.03.007","volume":"26","author":"X Zhu","year":"2004","unstructured":"Zhu X, Topouzis S, Liang LF, Stotish RL. Myostatin signaling through Smad2, Smad3 and Smad4 is regulated by the inhibitory Smad7 by a negative feedback mechanism. Cytokine. 2004;26:262\u201372.","journal-title":"Cytokine"},{"key":"3622_CR41","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1096\/fasebj.13.15.2105","volume":"13","author":"E Piek","year":"1999","unstructured":"Piek E, Heldin C, Ten Dijke P. Specificity, diversity, and regulation in TGF-\u03b2 superfamily signaling. FASEB J. 1999;13:2105\u201324.","journal-title":"FASEB J"},{"key":"3622_CR42","doi-asserted-by":"publisher","unstructured":"Kim JR, Pham THN, Kim WU, Kim HA. A causative role for periarticular skeletal muscle weakness in the progression of joint damage and pain in OA. Sci Rep. 2023;13. https:\/\/doi.org\/10.1038\/S41598-023-46599-7.","DOI":"10.1038\/S41598-023-46599-7"},{"key":"3622_CR43","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1002\/jbmr.4529","volume":"37","author":"CL Omosule","year":"2022","unstructured":"Omosule CL, Joseph D, Weiler B, Gremminger VL, Silvey S, Jeong Y, et al. Combinatorial inhibition of myostatin and activin A improves femoral bone properties in the G610C mouse model of osteogenesis imperfecta. J Bone Min Res. 2022;37:938\u201353.","journal-title":"J Bone Min Res"},{"key":"3622_CR44","doi-asserted-by":"publisher","unstructured":"Bunn RC, Adatorwovor R, Smith RR, Ray PD, Fields SE, Keeble AR, et al. Pharmacologic inhibition of myostatin with a myostatin antibody improves the skeletal muscle and bone phenotype of male insulin-deficient diabetic mice. JBMR Plus 2023;7. https:\/\/doi.org\/10.1002\/JBM4.10833.","DOI":"10.1002\/JBM4.10833"},{"key":"3622_CR45","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1177\/0300985815586223","volume":"52","author":"JK Simmons","year":"2015","unstructured":"Simmons JK, Hildreth BE, Supsavhad W, Elshafae SM, Hassan BB, Dirksen WP, et al. Animal models of bone metastasis. Vet Pathol. 2015;52:827\u201341.","journal-title":"Vet Pathol"},{"key":"3622_CR46","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/978-1-0716-1258-3_4","volume":"2274","author":"T Kuchimaru","year":"2021","unstructured":"Kuchimaru T, Kizaka-Kondoh S. A murine bone metastasis model using caudal artery injection and bioluminescence imaging. Methods Mol Biol. 2021;2274:37\u201342.","journal-title":"Methods Mol Biol"},{"key":"3622_CR47","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1111\/bjh.12835","volume":"165","author":"KM Abdulkadyrov","year":"2014","unstructured":"Abdulkadyrov KM, Salogub GN, Khuazheva NK, Sherman ML, Laadem A, Barger R, et al. Sotatercept in patients with osteolytic lesions of multiple myeloma. Br J Haematol. 2014;165:814\u201323.","journal-title":"Br J Haematol"},{"key":"3622_CR48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13058-020-01269-8","volume":"22","author":"MT Haider","year":"2020","unstructured":"Haider MT, Saito H, Zarrer J, Uzhunnumpuram K, Nagarajan S, Kari V, et al. Breast cancer bone metastases are attenuated in a Tgif1-deficient bone microenvironment. Breast Cancer Res. 2020;22:1\u201316.","journal-title":"Breast Cancer Res"},{"key":"3622_CR49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1559-0275-11-4","volume":"11","author":"Y Kawashima","year":"2014","unstructured":"Kawashima Y, Kodera Y, Singh A, Matsumoto M, Matsumoto H. Efficient extraction of proteins from formalin-fixed paraffin-embedded tissues requires higher concentration of tris(hydroxymethyl)aminomethane. Clin Proteom. 2014;11:1\u20136.","journal-title":"Clin Proteom"}],"container-title":["Oncogene"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41388-025-03622-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41388-025-03622-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41388-025-03622-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T23:02:44Z","timestamp":1764198164000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41388-025-03622-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,17]]},"references-count":49,"journal-issue":{"issue":"49","published-print":{"date-parts":[[2025,12,18]]}},"alternative-id":["3622"],"URL":"https:\/\/doi.org\/10.1038\/s41388-025-03622-7","relation":{},"ISSN":["0950-9232","1476-5594"],"issn-type":[{"value":"0950-9232","type":"print"},{"value":"1476-5594","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,17]]},"assertion":[{"value":"22 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All methods were performed in accordance with the relevant guidelines and regulations. The ethics approval for human tissue and plasma samples from BC patients has been obtained by the Ethik-Kommission der \u00c4rztekammer Westfalen-Lippe und Universit\u00e4t Muenster, Germany (file number 2020-797-f-S and 2020-172-b-S). Informed consent was obtained from all participants. All animal experiments were approved by the local authorities (Landesamt f\u00fcr Natur-, Umwelt- und Verbraucherschutz; LANUV; permits 84-02.04.2019.A184).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}